Photo of Dr. Pranesh Chakraborty

Dr. Chakraborty is a physician certified by the Royal College in Medical Biochemistry and Pediatrics, with a subspecialty in Biochemical Genetics. He joined CHEO in 2003 as a clinician seeing patients with inborn errors of metabolism. In 2006 he led the transition of Ontario’s newborn screening program to Ottawa leading to the establishment of Newborn Screening Ontario (NSO) at CHEO.

In 2008 he was instrumental in the founding of the Better Outcomes Registry and Network (BORN Ontario) at CHEO as a prescribed registry in Ontario, and was the Medical Director of BORN until 2017.

 At NSO, the research program focuses on developing novel laboratory methods and clinical biomarkers, most recently using metabolomics and genomics, studying policy, and clinical research in newborn screening.

 In addition to leading the research program within NSO, Dr. Chakraborty is a Principal Investigator for the Canadian Inherited Metabolic Disease Research Network (CIMDRN) (hyperlink www.CIMDRN.ca) which has received over $2M in CIHR funding since its inception to support rare disease research, in order to improve patient care experiences and outcomes in this population.

 Dr. Chakraborty is a Co-Principal Investigator with Dr. Kumanan Wilson and Dr. Steven Hawken at The Ottawa Hospital to assess the feasibility of using newborn heel prick blood samples to estimate gestational age infants in low-resource settings. Families are also able to receive newborn screening for select diseases, similar to what is offered to babies here in Ontario. Overall, this project has received $2.5 million USD from the Bill & Melinda Gates Foundation.